²Ä 38 ´Á 2004-03-26

¬ã¨sµo®i
¥xÆW­ì¦í¥Áµh­·¤§¿ò¶Ç³sÂê¤ÀªR¡G¤â¨¬°t¹ï³sÂê¤ÀªR¤Î¦X¨Ö¶Ç»¼³sÂꤣ¥­¿ÅÀË©w¬ã¨s

°ê®a½Ã¥Í¬ã¨s°|Àô¹Ò»P¾·~¯f¬ã¨s²Õ¸¯À³´Ü¬ã¨s­û¦b¥xÆW­ì¦í¥Áµh­·°ò¦]¦ì¸m¤§¬ã¨s¦³­«­n¶i®i¡C

¥xÆW­ì¦í¥Á¦³«Ü°ªªºµh­·»P°ª§¿»Ä¦å¯gªº²±¦æ²v¡Aµh­·ªº§Î¦¨°£¤FÀô¹Ò¦]¯À¥~¡A¿ò¶Ç¦]¯À¤]¦³¥²­n±´°Q¡CµÇŦ¬O¤HÅé¥NÁ§¿»ÄÆQ³Ì­«­nªº¾¹©x¡AµÇŦ­Y¬Oµo¥Í¯fÅÜ¡A½Õ±±§¿»ÄªºùÚ©w«K¾D¨ü¯}Ãa¡C

¥»¬ã¨s±´°QÅé¬V¦âÅéÅã©Ê¿ò¶ÇªºÅè½èÅnª¬µÇŦ¯f (Autosomal-dominant medullary cystic kidney disease, ²ºÙ ADMCKD) »Pµh­·ªºÃö«Y¡C§Q¥Î¤â¨¬°t¹ï³sÂê¤ÀªR¬ã¨s¤Î¦X¨Ö¶Ç»¼¤£¥­¿ÅÀË©w¡A±´°Q­ì¦í¥Á®a±Ú©Êµh­·ªº­P¯f°ò¦]®y¡A¬O§_¤]¦ì©ó²Ä¤@¸¹¬V¦âÅé1q21ªº¦ì¸m¡C

¥»¬ã¨s¦@¦¬¶°¤F767¤Hªº®a±Ú¥v¸ê®Æ¡A¨ä¤¤²Å¦X¤â¨¬°t¹ï¤ÀªR¤Î¦X¨Ö¶Ç»¼¤£¥­¿ÅÀË©wªº¬ã¨s¹ï¶H¡A¦³DNA ÀËÅéªÌ127¤H¡A¨ä¤¤µh­·±wªÌ89¤H¡AµLµh­·ªÌ38¤H¡F¨k©Ê95¤H¡A¤k©Ê32¤H¡A¦@112¹ï¤â¨¬¡B25­Ó®a±Ú¥]§t36­Ó®Ö¤ß®a®x¡C­º¥ý§Q¥Î¿ò¶Ç¬y¦æ¯f¾Ç²Î­p®M¸Ë³nÅé (Statistical analysis of genetic epidemiology version 3.1¡A²ºÙS.A.G.E. 3.1ª©¥») ¤¤SIBPALµ{¦¡¶i¦æ¤â¨¬°t¹ï³sÂê¤ÀªR¡C µ²ªGµo²{¤@³s¦ê¬Û¾Fªº°ò¦]¼Ð°O¬ÒÅã¥Ü¨ã¦³ÅãµÛ©Êªº³sÂê (significant linkage)¡G§YD1S498 (°jÂk«Y¼Æ¬° -0.52)¡BD1S2635 (-0.47) ¤ÎD1S196 (-0.51)¡AP­È < 0.005¡F¥t¥~D1S252 (-0.32)¡BD1S484 (-0.34) ¤ÎD1S2878 (-0.38)¡AP­È < 0.05¡C¥t¥~¦b¦³³sÂꪺ±¡§Î¤U¡A¦X¨Ö³sÂꤣ¥­¿ÅÀË©wªkªºµ²ªGÅã¥Ü¦b¿ò¶Ç¼Ð°OD1S484¦³³sÂꤣ¥­¿Åªº±¡§Î¡A¨ä©Ò¾Ö¦³ªº4­Ó¹ï°¸°ò¦]¤¤ªº1¸¹¹ï°¸°ò¦]¡A¦³¤ñ¸û°ªªºÀW²v¥Ñ¿Ë¥N³Q¶Ç»¼µ¹¦³¯fªº¤l¥N¡C¥»¶µ¬ã¨s´£¨Ñ¤FÃÒ¾ÚÅã¥Ü­ì¦í¥Á®a±Ú©Êªºµh­·¡A¨ü¨ì°ò¦]½Õ±±ªº¼vÅT¡A¨ä­Ô¿ï°ò¦]®yªº¦ì¸m¡A¥i¯àÁôÂæb²Ä¤@¸¹¬V¦âÅé1q21ªº°Ï°ì¨ì1q22ªºÃä½t¡C

¸¯À³´Ü¬ã¨s­û¤§¬ã¨sµo²{¡A¼¶¼g½×¤å¤wµoªí©ó°ê»Ú¬ì¾Ç´Á¥Z¡A½×¤åÃD¥Ø¬°Complex Segregation and Linkage Analysis of Familial Gout in Taiwanese Aborigines. Arthritis and Rheumatism 50: 242-246, 2004¡C
¡m¤å¡GÀô¹Ò»P¾·~¯f¬ã¨s²Õ¡F¹Ï¡G¥k¤@¬°¸¯À³´Ü¬ã¨s­û¡n

¤H¨Æ°ÊºA
ºë¯«Âå¾Ç»PÃĪ«Àݥάã¨s²Õ²Õ¥D¥ôªL§J©ú±Ð±Â¨ì¥ô

ºë¯«Âå¾Ç»PÃĪ«Àݥάã¨s²Õ²Õ¥D¥ôªL§J©ú±Ð±Â©ó93¦~3¤ë15¤é¨ì¥ô¡C°ê®a½Ã¥Í¬ã¨s°|§¹¦¨«Ø°|­pµe­ì¥ý©Ò³W¹º¤Q­Ó¬ã¨s²Õ¤§¨Ï©R¡C

ªL§J©ú²Õ¥D¥ô²¦·~©ó°ê¥ß¥xÆW¤j¾ÇÂå¾Ç°|,¦b1972-1977´Á¶¡©ó¥x¤jÂå°|¤ÎµØ²±¹y¤j¾Ç±µ¨ü§¹¾ãªº¦í°|Âå®v°V½m¡A1977-1979 Àò±o¤½¦@½Ã¥ÍºÓ¤h¾Ç¦ìªº¦P®É¤]±µ¨ü¹w¨¾Âå¾Ç¤§¹ê²ß°V½m¡C¦Û1979¦~°_¥ô¾©ó´ä°Ï¥[¦{¤j¾Ç¬¥§üÁF¤À®Õ(Harbor-UCLA) Âå¾Ç¤¤¤ß¡A»â¦³¬ü°ê¤Î¥xÆWºë¯«Âå¾Ç¤§±M·~ÃҮѡC¦b¬ü°ê®È©~´Á¶¡¥ô¾©ó¥[¦{¤j¾Ç¬¥§üÁF¤À®Õ¾á¥ôºë¯«Âå¾Ç±Ð±Â¥H¤ÎHarbor-UCLA ±Ú¸Ç¥Íª«ºë¯«Âå¾Ç¬ã¨s¤¤¤ß¥D¥ô¡CªL±Ð±Â­P¤O©ó¸óºØ±Ú¤å¤Æ¤§ºë¯«Âå¾Ç»â°ìªø¹F30¦h¦~¤§¤[¡C¦bºØ±Úºë¯«ÃIJz¾Ç¡Bºë¯«¯e¯f¤ÀÃþ¾Ç¤è­±ªº¬ã¨s¥~¡A¦bºë¯«¬y¦æ¯f¾Ç¡B°sÅ}¡BÂåÀø¤HÃþ¾Ç¤ÎÃø¥Á¤ß²z¾Çµ¥¤è­±¤]¦³²`¤Jªº¬ã¨s¡A¦P®É¦b¬¥§üÁF¨­¬°¨â­Ó¨È¤Ó¸ÇªÀ°Ïºë¯««O°·¤¤¤ßªº³Ð©l¤H¡A¨ä¹ïºë¯«Âå¾Ç»â°ì¨ô¦³°^Äm¡C

ªL±Ð±Â¥Ø«e­P¤O©ó ¿ò¶ÇÃĪ«¾Ç¬ã¨s(Pharmacogenetics) »Pºë¯«ÃĪ«ªvÀøªº ÃĪ«°ò¦]Åé¬ã¨s (Pharmacogenomics in psychopharmacotherapeutics) ¡A ¨Ã¨Ï¥Î¥ý¶iªº»ö¾¹¤u¨ã¨Ó¿Å¶q¦]¤£¦P­ÓÅé¤Î¸óºØ±Ú¤å¤Æ¦bºë¯«²§±`¤ÏÀ³¤Wªº¬Û²§¤§³B¡A ´Á«Ý¥H¦¹±À°Ê¡u­ÓÅé¤ÆÂå¾Ç¡]Individualized medicine¡^¡v¡C ªL±Ð±Â¦b¤W­z¬ÛÃö»â°ìµÛ§@»áÂסC¦­´Á´NŪÂå¾Ç°|´Á¶¡¡A¥ç´¿Â½Ä¶¦ò¬¥¨Ì¼w¤Î±ö¹ç®æµ¥ºë¯«Âå¾Ç¤j®vªºµÛ§@¡CªL±Ð±Â¦h¦~©ó¬ü°ê¡B¥xÆW¤Î¥@¬É¦U¦a±q¨Æ¾Ç³NºtÁ¿¡A¾á¥ô¦hºØ¬ã¨sÂåÀø¾÷ºc(¨Ò¦p¡GNIMH, FDA) ¤Î°ê»ÚÂå¾ÇÂø»x¤§µû¼f­û¡A¨Ã¦P®É¾á¥ô¼Æ­Ó°ê»Ú²Õ´¤§¿Ô¸ß©e­û·|¤§©e­û (¥]¬AAPAªº¬ã¨s¨ó½Õ·|¤ÎDSM-V ¤u§@¤p²Õ)¡A³Ìªñ¥ç¨üÁܾá¥ô¾¥º¸¥»¤j¾Çº[«¢¦òÂå¾Ç°|ºë¯«°·±d»â¾É­pµe(iMHLP)¤§°ê»Ú¿Ô¸ß©e­û·|©e­û¡C´¿¾á¥ô¤¤°ê´ò«n¤j¾Ç¤§ºaÅA±Ð±Â¡A ­^°ê¬Ó®aºë¯«Âå¾Ç°|William SargantÁ¿­û(2000)¡A¥H¤ÎÀò±oAPA's Kung-Po Soo Asian American Award (2002)¡C

ªL±Ð±Â¦^°ê«á»P¦P¤¯²Ä¤@¦¸½Í¸Ü¥O¤H¦L¶H²`¨è¡A¥L»¡¡u¦h¦~¨Ó®É®É±}°OµÛ¬°°ê¤HªA°Èªº¾÷·|¡A ¤µ¤Ñ²×©ó¹Ú·Q¦¨¯u!¡v °ê®a½Ã¥Í¬ã¨s°|¾ú¸g¦h¦~²×©ó«Ø¥ß³W¹º¤¤ªº¤Q­Ó¬ã¨s²Õ¡A³o¦ó¹Á¤£¬O¡u¹Ú·Q¦¨¯u¡vªº®É¨è¡A¥¼¨Ó¹w´Á­É­«ªL±Ð±ÂÂ×´IªºÁ{§ÉÂå¾Ç¬ã¨s¸gÅç¤Î»â¾É¯à¤O¡A¬°¥[³tµo®i°ê¤ººë¯«Âå¾Ç»PÃĪ«Àݥάã¨s¦Ó§V¤O¡C
¡m¤å¡GªL¨Îå¢; Äá¼v¡G¶À·R¯u¡n

°|°È¬ö¨Æ
¦Ñ¦~Âå¾Ç¦¸±M¬ìÂå®v°V½m¾Ç­ûµû¿ïµ²ªG

°ê®a½Ã¥Í¬ã¨s°|¦Ñ¦~Âå¾Ç¬ã¨s²Õ¿ì²z¡u¦Ñ¦~Âå¾Ç¦¸±M¬ìÂå®v°V½m½Òµ{¡v¾Ç­û¼x¿ï¡AÀò±o¦h®aÂå°|¤ä«ù¡A¸g®Ñ­±¼f¬d»P­±¸Õµ{§Ç¡A·~¤w§¹¦¨µû¿ï§@·~¡A¿ý¨ú¾Ç­û¦@8¦W¡A¦W³æ¦p¤U¡G

¤T­xÁ`Âå°|®a®xÂå¾Ç¬ì°ªªFÞmÂå®v¡F
¤¤¤sÂå¾Ç¤j¾Çªþ³]Âå°|®a®xÂå¾Ç¬ì¤ý¥Î¦ëÂå®v¡F
¥x¤jÂå°|¤º¬ì³¡§f¥ç¼ÏÂå®v¡B§d¬F¿«Âå®v;
¥x¤jÂå°|®a®xÂå¾Ç³¡¿à¨q©ûÂå®v¡F
ªL¤fªø©°Âå°|¤º¬ìªL©v»¨Âå®v¡B¹ù°ê¦ÚÂå®v¡F
¤Ñ¥D±Ð¯Ñ²ñÂå°|®a®xÂå¾Ç¬ìªL©É§gÂå®v¡C

¥¿¦¡°Ñ°V¦W³æ¥H2004-03-26¤W¤È10®É©ó°ê®a½Ã¥Í¬ã¨s°|¤º´ò°|°Ï3FªA°È¥x°¼µoº]¤½§i¬°·Ç¡A¨Ã¦P®É¤½¥¬©ó°ê®a½Ã¥Í¬ã¨s°|ºô¯¸¡C

¦Ñ¦~Âå¾Ç¦¸±M¬ìÂå®v°V½m½Òµ{¦®¦b°ö¨|Àu¨q¦Ñ¦~Âå¾Ç¦¸±M¬ìÂå®v¡A¥H´£ª@¦Ñ¤HÂåÀø·ÓÅ@¤ô·Ç¡A¬°¦U±Ð¾ÇÂå°|°V½mºØ¤l®v¸ê¡A°V½m¤º®e¥]¬A¡G¯«¸g¬ì¡Bºë¯«¬ì¡B´_°·¬ì¡B¦Ñ¦~¬ì«æ©Ê¯f©Ð¡B¦Ñ¦~ªø´Á·ÓÅ@¡B¦Ñ¦~¬ìªù¶E¡B·Ó·|ªA°È¤Î¦Ñ¦~Âå¾Ç¬ÛÃö¤§¾Ç³N¬¡°Ê¡A¥Ñ°ê®a½Ã¥Í¬ã¨s°|¦Ñ¦~Âå¾Ç¬ã¨s²Õ¥D¥ôÀ¹ªF­ì±Ð±Â¾á¥ô½Òµ{¥D«ù¤H¡A¨Ã©µ¸u¦h¦ì°ê¤º¥~¬ÛÃö»â°ì®v¸ê±Â½Ò¡C
¡m¤å¡G§õ·ç§D¡FÄá¼v¡G³¯ÄR¬î¡n

¼x¤~§Ö°T
Àô¹Ò½Ã¥Í»P¾·~Âå¾Ç¬ã¨s²Õ¸Û¼x²Õ¥D¥ô

°ê®a½Ã¥Í¬ã¨s°|¬°°]¹Îªk¤H¾Ç³N¬ã¨s¾÷ºc¡A¸Û¼°ÁܽвŦX±ø¥ó¤§¥Ó½Ð¤HÀ³¼xÀô¹Ò½Ã¥Í»P¾·~Âå¾Ç¬ã¨s²Õ²Õ¥D¥ô¤A¾¡C

¬ã¨s²Õ²Õ¥D¥ô¶·­t³d³W¹º¡Bµo®i¡B°õ¦æ¡B´£ª@¨Ã¾ã¦X°ê¤º¬ÛÃöªºÀô¹Ò½Ã¥Í»P¾·~Âå¾Ç¤§¬ã¨s¡A¥Ó½Ð¤H¶·¨ã¥Í©R¬ì¾Ç³Õ¤h©ÎÂå¾Ç¤h¾Ç¦ì¡A´¿¾á¥ô¬ã¨s³æ¦ì¥DºÞ¨ã¤­¦~¥H¤W¤§¸gÅç¡C¨ã¨ô¶V»â¾É¯S½è¡A´I¶}³Ð¤Î·¾³q¯à¤O¡A¼ô±x°ê¤º¦U¶µÀô¹Ò½Ã¥Í»P¾·~Âå¾Ç°ÝÃD¡C
ºI¤î¤é´Á¡G93¦~4¤ë30¤é
ºô§}¡G²Ó¸`»P¥Ó½Ð¸ê®Æ½Ð°Ñ¦Ò¥»°|ºô¯¸ http://www.nhri.org.tw >>¼x¤~§Ö°T
¡m¤å¡G±i¤å¥¿¡n